← Back to Search


AB-205 for Lymphoma (E-CELERATE Trial)

Phase 3
Waitlist Available
Research Sponsored by Angiocrine Bioscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 21 days
Awards & highlights


This trial is testing a drug to see if it can prevent or reduce severe complications from high-dose chemotherapy in lymphoma patients.

Who is the study for?
Adults over 40 with Hodgkin or non-Hodgkin lymphoma, in partial or complete remission, can join this trial. They must be fit enough for high-dose chemotherapy and stem cell transplant, have good heart and lung function, normal liver enzymes, a creatinine clearance of at least 30 ml/min, and not exceed a certain weight limit. Participants must agree to use two forms of contraception if they are sexually active.Check my eligibility
What is being tested?
The study tests whether AB-205 can prevent or lessen severe complications from high-dose chemotherapy in lymphoma patients undergoing stem cell transplants compared to a placebo. All participants will receive standard care alongside the test drug or placebo.See study design
What are the potential side effects?
Potential side effects aren't specified here but may include reactions related to immune system suppression due to chemotherapy and transplantation procedures such as infections, bleeding issues, nausea, fatigue among others.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 21 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The absence of oral/GI severe regimen related toxicities (oral/GI SRRT).
Secondary outcome measures
Duration of febrile neutropenia
Duration of oral/GI SRRT
Symptom burden per MD Anderson Symptom Inventory (MDASI)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AB-205 plus standard-of-care preventive and supportive therapies.Experimental Treatment1 Intervention
Group II: Placebo plus standard-of-care preventive and supportive therapies.Placebo Group1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Non-Hodgkin's Lymphoma (NHL) include high-dose chemotherapy followed by blood stem cell transplantation. High-dose chemotherapy targets and kills rapidly dividing cancer cells but also harms healthy tissues, causing severe complications. Blood stem cell transplantation helps regenerate the bone marrow's ability to produce blood cells post-chemotherapy. The experimental therapy AB-205 is being studied to prevent or reduce these chemotherapy-related complications, which is vital for improving patient outcomes and minimizing hospitalization and life-threatening risks.

Find a Location

Who is running the clinical trial?

Angiocrine BioscienceLead Sponsor
5 Previous Clinical Trials
117 Total Patients Enrolled
California Institute for Regenerative Medicine (CIRM)OTHER
65 Previous Clinical Trials
3,045 Total Patients Enrolled
Paul Finnegan, MDStudy DirectorAngiocrine Bioscience, Inc.
2 Previous Clinical Trials
52 Total Patients Enrolled

Media Library

AB-205 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05181540 — Phase 3
Non-Hodgkin's Lymphoma Research Study Groups: AB-205 plus standard-of-care preventive and supportive therapies., Placebo plus standard-of-care preventive and supportive therapies.
Non-Hodgkin's Lymphoma Clinical Trial 2023: AB-205 Highlights & Side Effects. Trial Name: NCT05181540 — Phase 3
AB-205 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05181540 — Phase 3
~39 spots leftby Jul 2025